Dr John Staffurth

2021

• Day, E.et al. 2021. Feasibility of comparative health research outcome of novel surgery in prostate cancer (IP4-CHRONOS): statistical analysis plan for the randomised feasibility phase of the CHRONOS study. Trials 22(1), article number: 547. (10.1186/s13063-021-05509-w)
• Piazzese, C.et al. 2021. FIELDRT: an open-source platform for the assessment of target volume delineation in radiation therapy. British Journal of Radiology 94(1126), article number: 20210356. (10.1259/bjr.20210356)
• Adamson, D.et al. 2021. Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial. Lancet Gastroenterology and Hepatology 6(4), pp. 292-303. (10.1016/S2468-1253(21)00004-2)
• Sutton, E.et al. 2021. Men's experiences of radiotherapy treatment for localized prostate cancer and its long-term treatment side effects: a longitudinal qualitative study. Cancer Causes and Control 32(3), pp. 261–269. (10.1007/s10552-020-01380-3)
• Barrett, T.et al. 2021. Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting. BJU International 127(3), pp. 304-306. (10.1111/bju.15285)
• Connor, M. J.et al. 2021. Additional treatments to the local tumour for metastatic prostate cancer-assessment of novel treatment algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial. BMJ Open 11(2), article number: e042953. (10.1136/bmjopen-2020-042953)

2020

• Turnham, D. J.et al. 2020. The PTEN conundrum: how to target PTEN-deficient prostate cancer. Cells 9(11), article number: 2342. (10.3390/cells9112342)
• Reddy, D.et al. 2020. Comparative healthcare research outcomes of novel surgery in prostate cancer (IP4-CHRONOS): a prospective, multi-centre therapeutic phase II parallel randomised control trial. Contemporary Clinical Trials 93, article number: 105999. (10.1016/j.cct.2020.105999)
• Byrne, A. T.et al. 2020. Radiotherapy after esophageal cancer stenting (ROCS): A pragmatic randomized controlled trial evaluating the role of palliative radiotherapy in maintaining swallow.. Journal of Clinical Oncology 38(15_sup), article number: 4569. (10.1200/JCO.2020.38.15_suppl.4569)
• Murray, J.et al. 2020. Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial. European Urology 21, pp. 77-84. (10.1016/j.ctro.2019.12.006)
• Neal, D. E.et al. 2020. Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received. European Urology 77(3), pp. 320-330. (10.1016/j.eururo.2019.10.030)
• Farnell, D.et al. 2020. The ALERT-B questionnaire: a screening tool for the detection of gastroenterological late effects after radiotherapy for prostate cancer. Clinical and Translational Radiation Oncology 21, pp. 98-103. (10.1016/j.ctro.2020.02.002)
• Macnair, A.et al. 2020. The Trigger project: the challenge of introducing electronic patient-reported outcome measures into a radiotherapy service. Clinical Oncology 32(2), pp. e76-e79. (10.1016/j.clon.2019.09.044)
• Jacinta, A. and Staffurth, J. 2020. Hormonal therapy for cancer. Medicine 48(2), pp. 103-107. (10.1016/j.mpmed.2019.11.007)
• Murray, J.et al. 2020. A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer. Radiotherapy and Oncology 142, pp. 62-71. (10.1016/j.radonc.2019.10.017)

2019

• Wheeler, P. A.et al. 2019. Evaluating the application of Pareto navigation guided automated radiotherapy treatment planning to prostate cancer. Radiotherapy and Oncology 141, pp. 220-226. (10.1016/j.radonc.2019.08.001)
• Clark, E.et al. 2019. Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol. BMJ Open 9, article number: e034708. (10.1136/bmjopen-2019-034708)
• Payne, H.et al. 2019. Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uro-oncologists' opinions and practice. International Journal of Clinical Practice 73(9), pp. 1-6., article number: e13292. (10.1111/ijcp.13292)
• Hargreaves, S.et al. 2019. Interim 18F-FDG positron emission tomography/computed tomography during chemoradiotherapy in the management of cancer patients: a response [Letter]. Clinical Oncology 31(9), pp. 669-670. (10.1016/j.clon.2019.05.005)
• Cox, S.et al. 2019. Impact of deviations in target volume delineation - Time for a new RTQA approach?. Radiotherapy and Oncology 137, pp. 1-8. (10.1016/j.radonc.2019.04.012)
• Richards, R.et al. 2019. The preferences of patients with cancer regarding an app to help them to meet their illness-related information needs: a qualitative interview study. JMIR mHealth and uHealth 7(7), article number: e14187. (10.2196/14187)
• Whybra, P.et al. 2019. Assessing radiomic feature robustness to interpolation in 18F-FDG PET imaging. Scientific Reports 9(1), article number: 9649. (10.1038/s41598-019-46030-0)
• Nelson, A., Mann, M. and Staffurth, J. 2019. Methods of assessing late radiotherapy effects on bowel function. Current Opinion in Supportive and Palliative Care 13(2), pp. 134-141. (10.1097/SPC.0000000000000422)
• Parkinson, C.et al. 2019. Machine-learned target volume delineation of 18F-FDG PET images after one cycle of induction chemotherapy. Physica Medica, European Journal of Medical Physics 61, pp. 85-93. (10.1016/j.ejmp.2019.04.020)
• Foley, K. G.et al. 2019. External validation of a prognostic model incorporating quantitative PET image features in esophageal cancer. Radiotherapy and Oncology 133, pp. 205-212. (10.1016/j.radonc.2018.10.033)
• Jadon, R.et al. 2019. A systematic review of dose-volume predictors and constraints for late bowel toxicity following pelvic radiotherapy. Radiation Oncology 14(1), pp. -., article number: 57. (10.1186/s13014-019-1262-8)
• Wheeler, P. A.et al. 2019. Utilisation of Pareto navigation techniques to calibrate a fully automated radiotherapy treatment planning solution. Physics and Imaging in Radiation Oncology 10, pp. 41-48. (10.1016/j.phro.2019.04.005)
• Evans, E.et al. 2019. EP-1666 ARENA: Improving training in target volume delineation for radiotherapy. Radiotherapy and Oncology 133(S1), pp. S896-S897. (10.1016/S0167-8140(19)32086-9)
• Wheeler, P.et al. 2019. OC-0183 Multi-institutional evaluation of a Pareto navigation guided automated planning solution. Radiotherapy and Oncology 133(S1), pp. S92. (10.1016/S0167-8140(19)30603-6)
• Piazzese, C.et al. 2019. PO-0964 Stability and prognostic significance of CT radiomic features from oesophageal cancer patients. Radiotherapy and Oncology 133(S1), pp. S524-S525. (10.1016/S0167-8140(19)31384-2)
• Whybra, P.et al. 2019. PO-0963 A novel normalisation technique for voxel size dependent radiomic features in oesophageal cancer. Radiotherapy and Oncology 133(S1), pp. S523-S524. (10.1016/S0167-8140(19)31383-0)
• Whybra, P.et al. 2019. A novel normalisation technique for voxel size dependent radiomic features in oesophageal cancer [Abstract]. Radiotherapy and Oncology 133, pp. S523-S524. (10.1016/S0167-8140(19)31383-0)
• Dearnaley, D.et al. 2019. Toxicity and patient-reported outcomes of a phase 2 randomized trial of prostate and pelvic lymph node versus prostate only radiotherapy in advanced localised prostate cancer (PIVOTAL). International Journal of Radiation Oncology - Biology - Physics 103(3), pp. 605-617. (10.1016/j.ijrobp.2018.10.003)

2018

• Parkinson, C.et al. 2018. Dependency of patient risk stratification on PET target volume definition in oesophageal cancer. Presented at: ESTRO, Barcelona, Spain, 20-24 April 2018.
• Richards, R.et al. 2018. Use of mobile devices to help cancer patients meet their information needs in non-inpatient settings: systematic review. JMIR mHealth and uHealth 6(12), article number: e10026. (10.2196/10026)
• Woods, B. S.et al. 2018. Addition of Docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Modelling to estimate long-term survival, quality-adjusted survival, and cost-effectiveness. European Urology Oncology 1(6), pp. 449-458. (10.1016/j.euo.2018.06.004)
• Parkinson, C.et al. 2018. ATLAAS - Investigation into the incorporation of morphological data on automated segmentation. Presented at: EANM Congress 2018: European Association of Nuclear Medicine., Dusseldorf, Germany, 12-18 October 2018.
• Parkinson, C.et al. 2018. Target volume delineation of FDG PET images post one cycle of induction chemotherapy in oropharyngeal cancer using advanced automated segmentation methods. Presented at: ESTRO 37, Barcelona, 20-24 April 2018.
• Parkinson, C.et al. 2018. Evaluation of prognostic models developed using standardised image features from different PET automated segmentation methods. EJNMMI Research 8, article number: 29. (10.1186/s13550-018-0379-3)
• Donovan, J. L.et al. 2018. A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. Journal of Clinical Epidemiology 96, pp. 35-46. (10.1016/j.jclinepi.2017.12.019)
• Whybra, P.et al. 2018. Effect of interpolation on 3D texture analysis of PET imaging in oesophageal cancer. Radiotherapy and Oncology 127(S1), pp. S1164-S1165. (10.1016/S0167-8140(18)32426-5)
• Parkinson, C.et al. 2018. Target volume delineation of PET post one cycle of induction chemotherapy in oropharyngeal cancer. Radiotherapy and Oncology 127(S1), pp. S634-S635., article number: EP-1126. (10.1016/S0167-8140(18)31436-1)
• Parkinson, C.et al. 2018. Dependency of patient risk stratification on PET target volume definition in Oesophageal cancer. Radiotherapy and Oncology 127(S1), pp. S503-S504. (10.1016/S0167-8140(18)31241-6)
• Piazzese, C.et al. 2018. Evaluation of 2D and 3D radiomics features extracted from CT images of oesophageal cancer patients. Radiotherapy and Oncology 127, pp. S1180-S1181. (10.1016/S0167-8140(18)32450-2)

2017

• Wills, L.et al. 2017. Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy. Radiation Oncology 12(1), article number: 179. (10.1186/s13014-017-0916-7)
• Hurt, C. N.et al. 2017. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer. British Journal of Cancer 116(10), pp. 1264-1270. (10.1038/bjc.2017.95)
• Crosby, T.et al. 2017. Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/? cetuximab in oesophageal cancer. British Journal of Cancer 116(6), pp. 709-716. (10.1038/bjc.2017.21)

2016

• Gnanapragasam, V.et al. 2016. Clinical management and research priorities for high-risk prostate cancer in the UK: Meeting report of a multidisciplinary panel in conjunction with the NCRI Prostate Cancer Clinical Studies Localised Subgroup. Journal of Clinical Urology 9(6), pp. 369-379. (10.1177/2051415816651362)
• Taylor, S.et al. 2016. The three-item ALERT-B questionnaire provides a validated screening tool to detect chronic gastrointestinal symptoms after pelvic radiotherapy in cancer survivors. Clinical Oncology 28(10), pp. e139-e147. (10.1016/j.clon.2016.06.004)
• Johnston, T. J.et al. 2016. Mortality among men with advanced prostate cancer excluded from the ProtecT trial. European Urology 71(3), pp. 381-388. (10.1016/j.eururo.2016.09.040)
• Taylor, S.et al. 2016. Improving the well-being of men by Evaluating and Addressing the Gastrointestinal Late Effects (EAGLE) of radical treatment for prostate cancer: study protocol for a mixed-method implementation project. British Medical Journal Open 6(10), article number: e011773. (10.1136/bmjopen-2016-011773)
• Tanguay, J. S.et al. 2016. High risk of neutropenia for hormone-naive prostate cancer patients receiving STAMPEDE-style upfront Docetaxel chemotherapy in usual clinical practice. Clinical Oncology 28(9), pp. 611-611. (10.1016/j.clon.2016.03.006)
• Fokas, E.et al. 2016. Comparison of investigator-delineated gross tumour volumes and quality assurance in pancreatic cancer: analysis of the on-trial cases for the SCALOP trial. Radiotherapy and Oncology 120(2), pp. 212-216. (10.1016/j.radonc.2016.07.002)
• Dearnaley, D.et al. 2016. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncology 17(8), pp. 1047-1060. (10.1016/S1470-2045(16)30102-4)
• James, N.et al. 2016. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health Technology Assessment 20(53) (10.3310/hta20530)
• Andronis, L.et al. 2016. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU International 119(4), pp. 522-529. (10.1111/bju.13549)
• Gwynne, S.et al. 2016. Prospective review of radiotherapy trials through implementation of standardised multi-centre workflow and IT infrastructure. British Journal of Radiology 89, article number: 20160020. (10.1259/bjr.20160020)
• Fokas, E.et al. 2016. P-222 Analysis of tumour contours and radiotherapy planning of 'on-trial' patients undergoing chemoradiotherapy (CRT) in SCALOP trial: does pre-trial Radiotherapy Quality Assurance (RTQA) improve the quality of 'on-trial' radiotherapy?. Annals of Oncology 27(sup. 2), pp. ii64.3-ii65. (10.1093/annonc/mdw199.214)
• Sharma, R. A.et al. 2016. Clinical development of new drug-radiotherapy combinations. Nature Reviews Clinical Oncology 13, pp. 627-642. (10.1038/nrclinonc.2016.79)
• James, N. D.et al. 2016. Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both. JAMA Oncology 2(4), pp. 493-499. (10.1001/jamaoncol.2015.5570)
• Carrington, R.et al. 2016. The influence of dose distribution on treatment outcome in the SCOPE 1 oesophageal cancer trial. Radiation Oncology 11, article number: 19. (10.1186/s13014-016-0594-x)
• Carrington, R.et al. 2016. The influence of radiotherapy treatment method on dose distribution and its relation to patient outcome in the SCOPE 1 oesophageal cancer trial using Type B algorithms. Radiation Oncology (London, England) 11, article number: 19. (10.1186/s13014-016-0594-x)
• Abraham, J. and Staffurth, J. N. 2016. Hormonal therapy for cancer. Medicine 44(1), pp. 30-33. (10.1016/j.mpmed.2015.10.014)
• Taylor, S. E.et al. 2016. Late effects of pelvic radiation treatment (EAGLE study) [Abstract]. Journal of Clinical Oncology 34(3), pp. 159. (10.1200/jco.2016.34.3_suppl.159)

2015

• Fokas, E.et al. 2015. Comparison of investigator-delineated gross tumor volumes and quality assurance in pancreatic cancer: Analysis of the pretrial benchmark case for the SCALOP trial. Radiotherapy and Oncology 117(3), pp. 432-437. (10.1016/j.radonc.2015.08.026)
• Carrington, R.et al. 2015. The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: a radiobiological investigation. Radiation Oncology 10, article number: 236. (10.1186/s13014-015-0537-y)
• Hurt, C. N.et al. 2015. Health-related quality of life in SCALOP, a randomized phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer. International Journal of Radiation Oncology*Biology*Physics 93(4), pp. 810-818. (10.1016/j.ijrobp.2015.08.026)
• Hurt, C. N.et al. 2015. Health-related quality of life in SCALOP, a randomized Phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics 93(4), pp. 810-818.
• Rees, J.et al. 2015. Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer. British Journal of Cancer 113(4), pp. 603-610. (10.1038/bjc.2015.258)
• Harris, V. A.et al. 2015. Consensus guidelines and contouring atlas for pelvic node delineation in prostate and pelvic node intensity modulated radiation therapy. International Journal of Radiation Oncology*Biology*Physics 92(4), pp. 874-883. (10.1016/j.ijrobp.2015.03.021)
• Salimu, J.et al. 2015. Cross-Presentation of the Oncofetal Tumor Antigen 5T4 from Irradiated Prostate Cancer Cells—A Key Role for Heat-Shock Protein 70 and Receptor CD91. Cancer Immunology Research 3(6), pp. 678-688. (10.1158/2326-6066.CIR-14-0079)
• Carrington, R.et al. 2015. A radiobiological investigation of dose escalation in lower oesophageal tumours with a focus on gastric toxicity. Medical Physics 42(6), pp. 3346-3347. (10.1118/1.4924430)

2014

• Adamson, D.et al. 2014. Palliative radiotherapy in addition to self-expanding metal stent for improving dysphagia and survival in advanced oesophageal cancer (ROCS: Radiotherapy after Oesophageal Cancer Stenting): study protocol for a randomized controlled trial. Trials 15, article number: 402. (10.1186/1745-6215-15-402)
• Spary, L. K.et al. 2014. Enhancement of T cell responses as a result of synergy between lower doses of radiation and T cell stimulation. The Journal of Immunology 192(7), pp. 3101-3110. (10.4049/jimmunol.1302736)
• Jadon, R.et al. 2014. A systematic review of organ motion and image-guided strategies in external beam radiotherapy for cervical cancer. Clinical Oncology 26(4), pp. 185-196. (10.1016/j.clon.2013.11.031)
• Voskoboynik, M.et al. 2014. 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer. Expert Review of Anticancer Therapy 14(11), pp. 1253-1256. (10.1586/14737140.2014.971112)

2013

• Nixon, L. S.et al. 2013. The SCALOP Trial Plan Assessment Form (PAF) as a tool for Radiation Therapy Trials Quality Assurance (RTTQA). International Journal of Radiation Oncology*Biology*Physics 87(2), pp. S306. (10.1016/j.ijrobp.2013.06.804)
• Thomas, B. M.et al. 2013. Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy. Medical Oncology 30(4), article number: 719. (10.1007/s12032-013-0719-0)
• Crosby, T. D. L.et al. 2013. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. The Lancet Oncology 14(7), pp. 627-637. (10.1016/S1470-2045(13)70136-0)
• Mukherjee, S.et al. 2013. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. The Lancet Oncology 14(4), pp. 317-326. (10.1016/S1470-2045(13)70021-4)
• Crosby, T.et al. 2013. SCOPE 1: A phase II/III trial of chemoradiotherapy in esophageal cancer plus or minus cetuximab. American Journal of Clinical Oncology 31(Supp 4), article number: LBA3. (10.1200/jco.2013.31.4_suppl.lba3)
• Mukherjee, S.et al. 2013. Comparison of investigator-delineated GTV in chemoradiotherapy (CRT) for locally advanced nonmetastatic pancreatic cancer (LANPC): Analysis of the pretrial test case for the SCALOP trial. Journal of Clinical Oncology 31(4), article number: 230.
• Mukherjee, S.et al. 2013. SCALOP: Results of a randomized phase II study of induction chemotherapy followed by genicitabine (G) or capecitabine (Cap) based chentoradialion (CRT) in locally advanced pancreatic cancer (LANPC).. American Journal of Clinical Oncology 31(Supp 4)

2012

• Burnet, N. G.et al. 2012. Methodological considerations in the evaluation of radiotherapy technologies [Editorial]. Clinical Oncology 24(10), pp. 707-709. (10.1016/j.clon.2012.06.003)
• Hummel, S. R.et al. 2012. A model of the cost-effectiveness of intensity-modulated radiotherapy in comparison with three-dimensional conformal radiotherapy for the treatment of localised prostate cancer. Clinical Oncology 24(10), pp. e159-e167. (10.1016/j.clon.2012.09.003)
• Gwynne, S. H.et al. 2012. Toward semi-automated assessment of target volume delineation in radiotherapy trials: the SCOPE 1 pretrial test case. International Journal of Radiation Oncology*Biology*Physics 84(4), pp. 1037-1042. (10.1016/j.ijrobp.2012.01.094)
• Mayles, W. P. M.et al. 2012. Progress with intensity-modulated radiotherapy implementation in the UK. Clinical Oncology 24(8), pp. 543-544. (10.1016/j.clon.2012.06.005)
• Fizazi, K.et al. 2012. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology 13(10), pp. 983-992. (10.1016/S1470-2045(12)70379-0)
• Mackay, R. I.et al. 2012. Radiotherapy physics research in the UK: challenges and proposed solutions. British Journal of Radiology 85(1018), pp. 1354-1362. (10.1259/bjr/61530686)
• Spezi, E.et al. 2012. Patient-specific three-dimensional concomitant dose from cone beam computed tomography exposure in image-guided radiotherapy. International Journal of Radiation Oncology*Biology*Physics 83(1), pp. 419-426. (10.1016/j.ijrobp.2011.06.1972)
• Nilsson, S.et al. 2012. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. European Journal of Cancer 48(5), pp. 678-686. (10.1016/j.ejca.2011.12.023)
• Dearnaley, D.et al. 2012. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: Preliminary safety results from the CHHiP randomised controlled trial. The Lancet Oncology 13(1), pp. 43-54. (10.1016/S1470-2045(11)70293-5)
• Gwynne, S. H.et al. 2012. Image-guided radiotherapy for rectal cancer - A systematic review. Clinical Oncology 24(4), pp. 250-260. (10.1016/j.clon.2011.07.012)
• Gwynne, S.et al. 2012. Imaging for target volume delineation in rectal cancer radiotherapy - A systematic review. Clinical Oncology 24(1), pp. 52-63. (10.1016/j.clon.2011.10.001)

2011

• Gwynne, S.et al. 2011. Inter-observer variation in outlining of pre-trial test case in the SCOPE1 trial: A United Kingdom definitive chemoradiotherapy trial for esophageal cancer. International Journal of Radiation Oncology - Biology - Physics 81(2), pp. S67-S68. (10.1016/j.ijrobp.2011.06.135)
• de Bono, J. S.et al. 2011. Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine 364(21), pp. 1995-2005. (10.1056/NEJMoa1014618)
• Gwynne, S.et al. 2011. Imaging for rectal cancer radiotherapy - a systematic review. Clinical Oncology 23(3), pp. S37-S37.

2010

• Tabi, Z.et al. 2010. Resistance of CD45RA- T cells to apoptosis and functional impairment, and activation of tumor-antigen specific T cells during radiation therapy of prostate cancer. The Journal of Immunology 185(2), pp. 1330-1339. (10.4049/jimmunol.1000488)
• Welton, J. L.et al. 2010. Proteomics analysis of bladder cancer exosomes. Molecular & Cellular Proteomics 9(6), pp. 1324-1338. (10.1074/mcp.M000063-MCP201)
• Guerrero Urbano, T.et al. 2010. Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study. Clinical Oncology 22(3), pp. 236-244. (10.1016/j.clon.2010.01.005)
• Routsis, D.et al. 2010. Education and training for intensity-modulated radiotherapy in the UK. Clinical Oncology 22(8), pp. 675-680. (10.1016/j.clon.2010.06.012)
• Staffurth, J. N. 2010. A review of the clinical evidence for intensity-modulated radiotherapy. Clinical Oncology 22(8), pp. 643-657. (10.1016/j.clon.2010.06.013)
• Williams, M. V.et al. 2010. The implementation of intensity-modulated radiotherapy in the UK. Clinical Oncology 22(8), pp. 623-628. (10.1016/j.clon.2010.06.015)
• Mackay, R. I.et al. 2010. UK guidelines for the safe delivery of intensity-modulated radiotherapy.. Clinical Oncology 22(8), pp. 629-635.
• Button, M. R. and Staffurth, J. N. 2010. Clinical Application of Image-guided Radiotherapy in Bladder and Prostate Cancer. Clinical Oncology 22(8), pp. 698-706. (10.1016/j.clon.2010.06.020)
• Mukherjee, S.et al. 2010. A Cancer Research UK multicenter randomized phase II study of induction chemotherapy followed by gemcitabine- or capecitabine-based chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer. American Journal of Clinical Oncology 28

2009

• Jones, C. E.et al. 2009. The development and introduction of a written post-radiotherapy information leaflet for prostate cancer patients [Abstract]. Clinical Oncology 21(3), pp. 270. (10.1016/j.clon.2009.01.001)
• Nixon, L. S.et al. 2009. Implementation of a QA RT substudy for SCOPE 1; Preliminary results for test cases [Abstract]. Clinical Oncology 21(3), pp. 255-255. (10.1016/j.clon.2009.01.001,)
• Shelley, M. D.et al. 2009. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treatment Reviews 35(1), pp. 9-17. (10.1016/j.ctrv.2008.08.002)
• Mitchell, P. J.et al. 2009. Can urinary exosomes act as treatment response markers in prostate cancer?. Journal Of Translational Medicine 7(4), pp. n/a. (10.1186/1479-5876-7-4)
• Gwynne, S.et al. 2009. Respiratory movement of upper abdominal organs and its effect on radiotherapy planning in pancreatic cancer1. Clinical Oncology 21(9), pp. 713-719. (10.1016/j.clon.2009.07.015)
• Shelley, M. D.et al. 2009. Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials. Cancer Treatment Reviews 35(7), pp. 540-546. (10.1016/j.ctrv.2009.05.001)
• Wills, L.et al. 2009. The effect of planning algorithms in oesophageal radiotherapy in the context of the SCOPE 1 trial. Radiotherapy and Oncology 93(3), pp. 462-467. (10.1016/j.radonc.2009.08.036)
• Sutcliffe, P.et al. 2009. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Health Technology Assessment 13(5), pp. 1-242. (10.3310/hta13050)

2008

• Hudson, E.et al. 2008. Radiotherapy after radical prostatectomy for adenocarcinoma of the prostate: a UK institutional experience and review of published studies. Clinical Oncology 20(5), pp. 353-357. (10.1016/j.clon.2008.02.008)
• Abraham, J. and Staffurth, J. N. 2008. Hormonal therapy for cancer. Medicine 36(1), pp. 29-32. (10.1016/j.mpmed.2007.10.010)
• Abraham, J. and Staffurth, J. N. 2008. Hormones in cancer. In: Hanna, C. L., Crosby, T. and Macbeth, F. R. eds. Practical clinical oncology. Cambridge: Cambridge University Press, pp. 23-38.
• Barber, J. and Staffurth, J. N. 2008. Prostate. In: Hanna, C. L., Crosby, T. and Macbeth, F. R. eds. Practical clinical oncology. Cambridge: Cambridge University Press, pp. 231-239.
• Barber, J. and Staffurth, J. N. 2008. Testis. In: Hanna, C. L., Crosby, T. and Macbeth, F. R. eds. Practical clinical oncology. Cambridge: Cambridge University Press, pp. 240-251.
• Staffurth, J. N. and Mason, M. D. 2008. Radiotherapy for early prostate cancer. In: Kirk, D. ed. International handbook of prostate cancer. 3rd ed. Hampshire: Euromed Communications Limited, pp. 161-182.

2007

• Harnden, P.et al. 2007. Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. The Lancet Oncology 8(5), pp. 411-419. (10.1016/S1470-2045(07)70136-5)